Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris ...

Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for progression, according to a study published ...

MONDAY, Oct. 28, 2024 (HealthDay News) -- Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for ...

Though the strategic shift allows pharma to offer integrated health solutions, diversify revenue and improve patient outcomes ...

SLE patients were not included in clinical trials for SGLT2i, leaving uncertainty about whether the cardiorenal benefits of these medications apply to those with SLE and concurrent T2D. Karen H.

Medication abortions can be safely performed as early as the fourth week of pregnancy, researchers reported on Wednesday in ...

Over the last 7 days, the United States market has dropped 2.1%, yet it remains up 30% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech ...

Scpharmaceuticals ( (SCPH) ) has released its Q3 earnings. Here is a breakdown of the information Scpharmaceuticals presented to its investors.

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...